Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Alvotech and Finesse Solutions have entered into a partnership that will provide Alvotech with world-class, scalable, flexible and cost-efficient manufacturing and laboratory technology through the Finesse turnkey SmartFactory GMP manufacturing platform suite.
Subscribe to our email newsletter
SmartFactory is a single-use cGMP bio-manufacturing capacity, which will allow Alvotech to rapidly expand its biosimilars business. Finesse’s customers will benefit from unprecedented access to Alvogen’s commercial, the US Food and Drug Administration approved, biomanufacturing facility.
Alvotech CEO Dr Andreas Herrmann noted this partnership allows the company to leverage Finesse’s single-use bio-manufacturing automation platform, combining best-of-breed bio-process equipment from upstream through downstream.
"This strategic relationship provides us with much-needed additional manufacturing capacity and scale-up capabilities which will allow us to expedite our ambitions to become a global leader in the high-growth biopharmaceutical industry. The first manufacturing suite will be in place by the end of 2015," Dr Herrmann added.
Finesse CEO Dr Barbara Paldus said Alvotech is capitalizing on the extraordinary flexibility afforded by SmartFactory, and together the companies will be ableto implement cutting-edge, innovative solutions for established and development-stage biosimilars processes.
"The Alvotech facility will showcase our latest SMART technologies in process control, batch automation and data management. This partnership will also provide us with an important path to offer full-scale commercial manufacturing to our customers," Dr Paldus added.